A Phase 1 interventional study of STP7 (mavoglurant) and Placebo in Cocaine Use Disorder, sponsored by Stalicla SA. Completed at 1 site in United States. Open to participants aged 18 Years to 59 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Stalicla SA · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a double-blind, placebo-controlled, parallel group study to compare the effects of STP7 (mavoglurant) vs placebo control on i.v. cocaine's physiological and subjective effects in non-treatment seeking, cocaine-experienced males or females participants between 18 and 59 years of age.
The primary objective of this study is to determine if there are clinically meaningful interactions between oral STP7 (mavoglurant) treatment concurrent with 20 and 40 mg i.v. cocaine infusions by measuring adverse events and cardiovascular responses including heart rate, blood pressure, and electrocardiogram (including corrected QT interval).
The secondary objectives are:
Stalicla SA is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A female study participant must meet one of the following criteria:
If of - agrees to use one of the accepted regimens from at least 30 days prior to the first administration of the study medication, during the study, and for at least 30 days after the last dose of the study medication. An acceptable method of contraception includes one of the following:
i. Abstinence from heterosexual intercourse ii. Hormonal contraceptives (injectable/implant/insertable hormonal birth control products, transdermal patch) iii. Intrauterine device (with or without hormones) OR agrees to use a double barrier method (e.g. condom and spermicide) during the study and for at least 30 days after the last dose of the study medication. If a female of non-childbearing potential - should be surgically sterile (i.e. has undergone complete hysterectomy, bilateral oophorectomy, or tubal ligation/occlusion) or in a menopausal state (at least 1 year without menses), as confirmed by FSH levels.
A male study participant that engages in sexual activity that has the risk of pregnancy must agree to use a double barrier method (e.g. condom and spermicide) and agree to not donate sperm during the study and for at least 90 days after the last dose of the study medication.
Exclusion Criteria:
Have a history of liver disease or current elevation of liver function test (LFT) values as follows:
Have a history of renal disease or current renal function test values as follows:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will take STP7 (mavoglurant) twice a day (BID) from Days 3 to 9 according to the following dosing schedule: * Day 3: 50 mg BID; * Day 4: 100 mg BID; * Days 5-9: 200 mg BID, * Day 10: 200 mg only the morning dose. Morning STP7 (mavoglurant) doses must be taken within 30 minutes of beginning a meal.
Drug: STP7 (mavoglurant) · Drug: Cocaine Hydrochloride
Participants will take matched placebo twice a day (BID) from Days 3 to 9 and only the morning dose on Day 10. Morning Placebo must be taken within 30 minutes of beginning a meal.
Drug: Placebo · Drug: Cocaine Hydrochloride
STP7 (mavoglurant) twice a day (BID) from Days 3 to 9 according to the following dosing schedule: Day 3: 50 mg BID; Day 4: 100 mg BID; Days 5-9: 200 mg BID, and will take only the morning dose of STP7 (200 mg) on Day 10.
Also known as: AFQ056
Placebo twice a day (BID) from Days 3 to 9, and will take only the morning dose of Placebo on Day 10.
Participants will undergo cocaine/saline i.v. challenge sessions according to the schedule and doses: * Screening (Session 1, Day -2): 20 mg cocaine, followed by a saline infusion, followed by 40 mg cocaine * Baseline (Session 2, Day 1): saline or 20 mg cocaine followed by either 20 mg cocaine or saline. * Baseline (Session 3, Day 2): saline or 40 mg cocaine followed by either 40 mg cocaine or saline. * Treatment (Session 4, Day 9): saline or 20 mg cocaine followed by either 20 mg cocaine or saline. * Treatment (Session 5, Day 10): saline or 40 mg cocaine followed by either 40 mg cocaine or saline.
Incidence of Treatment-Emergent Adverse Events.
Any events spontaneously reported by the participant or observed by the investigative staff will also be recorded.
Time frame: On day -2, day -1, day 1, day 2, day 3, day 4, day 5, day 6, day 7, day 8, day 9, day10, day 11, day 12 and the follow-up (window from day 19 to day 26).
Heart Rate response following the STP7 treatment with the cocaine infusion.
Change of the Heart Rate.
Time frame: Collected at day -2 at the time points (relative to the first infusion of the day): -30, - 15, 5, 10, 15, 20, 25, 30, 45, 55, 65, 70, 75, 80, 85, 90, 105, 115, 125, 130, 135, 140, 145, 150, 165, 180, 210, 240, 270, 300, 330 and 360 minutes
Heart Rate response following the STP7 treatment with the cocaine infusion.
Change of the Heart Rate.
Time frame: Collected at day 1, day 2, day 9 and day 10 at the time points (relative to the first infusion of the day): -30, -15, 5, 10, 15, 20, 25, 30, 45, 55, 65, 70, 75, 80, 85, 90, 105, 120, 150, 180, 210, 240, 270 and 300 minutes
Blood Pressure (diastolic) response following the STP7 treatment with the cocaine infusion .
Change of the diastolic Blood Pressure.
Time frame: Collected at day -2 at the time points (relative to the first infusion of the day): -30, - 15, 5, 10, 15, 20, 25, 30, 45, 55, 65, 70, 75, 80, 85, 90, 105, 115, 125, 130, 135, 140, 145, 150, 165, 180, 210, 240, 270, 300, 330 and 360 minutes
Blood Pressure (diastolic) response following the STP7 treatment with the cocaine infusion.
Change of the diastolic Blood Pressure.
Time frame: Collected at day 1, day 2, day 9 and day 10 at the time points (relative to the first infusion of the day): -30, -15, 5, 10, 15, 20, 25, 30, 45, 55, 65, 70, 75, 80, 85, 90, 105, 120, 150, 180, 210, 240, 270 and 300 minutes
Blood Pressure (systolic) response following the STP7 treatment with the cocaine infusion.
Change of the systolic Blood Pressure.
Time frame: Collected at day -2 at the time points (relative to the first infusion of the day): -30, - 15, 5, 10, 15, 20, 25, 30, 45, 55, 65, 70, 75, 80, 85, 90, 105, 115, 125, 130, 135, 140, 145, 150, 165, 180, 210, 240, 270, 300, 330 and 360 minutes
Blood Pressure (systolic) response following the STP7 treatment with the cocaine infusion.
Change of the systolic Blood Pressure.
Time frame: Collected at day 1, day 2, day 9 and day 10 at the time points (relative to the first infusion of the day): -30, -15, 5, 10, 15, 20, 25, 30, 45, 55, 65, 70, 75, 80, 85, 90, 105, 120, 150, 180, 210, 240, 270 and 300 minutes
ECG changes (HR) following the STP7 treatment with the cocaine infusion.
Changes in ECG (HR) following STP7 treatment with the cocaine infusion at screening.
Time frame: As collected at day -2 at -10 minutes and at 5, 10, 15, 30, 45, 65, 70, 75, 90, 105, 125, 130, 135, 150, 165, 180 and 360 minutes after the first infusion.
ECG changes (RR) following the STP7 treatment with the cocaine infusion.
Changes in ECG (RR) following STP7 treatment with the cocaine infusion at screening.
Time frame: As collected at day -2 at -10 minutes and at 5, 10, 15, 30, 45, 65, 70, 75, 90, 105, 125, 130, 135, 150, 165, 180 and 360 minutes after the first infusion.
ECG changes (PR) following the STP7 treatment with the cocaine infusion.
Changes in ECG (PR) following STP7 treatment with the cocaine infusion at screening.
Time frame: As collected at day -2 at -10 minutes and at 5, 10, 15, 30, 45, 65, 70, 75, 90, 105, 125, 130, 135, 150, 165, 180 and 360 minutes after the first infusion.
ECG changes (QRS) following the STP7 treatment with the cocaine infusion.
Changes in ECG (QRS) following STP7 treatment with the cocaine infusion at screening.
Time frame: As collected at day -2 at -10 minutes and at 5, 10, 15, 30, 45, 65, 70, 75, 90, 105, 125, 130, 135, 150, 165, 180 and 360 minutes after the first infusion.
ECG changes (QT) following the STP7 treatment with the cocaine infusion.
Changes in ECG (QT) following STP7 treatment with the cocaine infusion at screening.
Time frame: As collected at day -2 at -10 minutes and at 5, 10, 15, 30, 45, 65, 70, 75, 90, 105, 125, 130, 135, 150, 165, 180 and 360 minutes after the first infusion.
ECG changes (HR) following the STP7 treatment with the cocaine infusion.
Changes in ECG (HR) following STP7 treatment with the cocaine infusion (baseline and treatment period).
Time frame: As collected at day 1, day 2, day 9 and day 10 at -10 minutes and at 5, 10, 15, 30, 45, 65, 70, 75, 90, 120, 150, 180 and 300 minutes after the first infusion.
ECG changes (RR) following the STP7 treatment with the cocaine infusion.
Changes in ECG (RR) following STP7 treatment with the cocaine infusion (baseline and treatment period).
Time frame: As collected at day 1, day 2, day 9 and day 10 at -10 minutes and at 5, 10, 15, 30, 45, 65, 70, 75, 90, 120, 150, 180 and 300 minutes after the first infusion.
ECG changes (PR) following the STP7 treatment with the cocaine infusion.
Changes in ECG (PR) following STP7 treatment with the cocaine infusion (baseline and treatment period).
Time frame: As collected at day 1, day 2, day 9 and day 10 at -10 minutes and at 5, 10, 15, 30, 45, 65, 70, 75, 90, 120, 150, 180 and 300 minutes after the first infusion.
ECG changes (QRS) following the STP7 treatment with the cocaine infusion.
Changes in ECG (QRS) following STP7 treatment with the cocaine infusion (baseline and treatment period).
Time frame: As collected at day 1, day 2, day 9 and day 10 at -10 minutes and at 5, 10, 15, 30, 45, 65, 70, 75, 90, 120, 150, 180 and 300 minutes after the first infusion.
ECG changes (QT) following the STP7 treatment with the cocaine infusion.
Changes in ECG (QT) following STP7 treatment with the cocaine infusion (baseline and treatment period).
Time frame: As collected at day 1, day 2, day 9 and day 10 at -10 minutes and at 5, 10, 15, 30, 45, 65, 70, 75, 90, 120, 150, 180 and 300 minutes after the first infusion.
Pharmacokinetics: Maximum Plasma Concentration [Cmax] of cocaine.
Plasma concentration-time profiles of cocaine.
Time frame: Day 2 and day 10: at 15 minutes before the first infusion, and at 5, 15, 30, 65, 75, 90, 120, 150, and 180 minutes, and at 4, 8, 12, 20 and 32 hours after the first infusion.
Pharmacokinetics: Maximum Plasma Concentration [Cmax] of benzoylecgonine.
Plasma concentration-time profiles of benzoylecgonine.
Time frame: Day 2 and day 10: at 15 minutes before the first infusion, and at 5, 15, 30, 65, 75, 90, 120, 150, and 180 minutes, and at 4, 8, 12, 20 and 32 hours after the first infusion.
Pharmacokinetics: Maximum Plasma Concentration [Cmax] of STP7.
Plasma concentration-time profiles of STP7.
Time frame: Day 5, day 6, day 7, day 8 and day 9: prior to the morning dose and 4 hours post-dose for each day.
Pharmacokinetics: Maximum Plasma Concentration [Cmax] of STP7.
Plasma concentration-time profiles of STP7.
Time frame: Day 10, at pre-dose, 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours post-dose.
Pharmacokinetics: time to maximum plasma concentration [Tmax] of cocaine.
Time to maximum plasma concentration of cocaine.
Time frame: Day 2 and day 10: at 15 minutes before the first infusion, and at 5, 15, 30, 65, 75, 90, 120, 150, and 180 minutes, and at 4, 8, 12, 20 and 32 hours after the first infusion.
Pharmacokinetics: time to maximum plasma concentration [Tmax] of benzoylecgonine.
Time to maximum plasma concentration of benzoylecgonine.
Time frame: Day 2 and day 10: at 15 minutes before the first infusion, and at 5, 15, 30, 65, 75, 90, 120, 150, and 180 minutes, and at 4, 8, 12, 20 and 32 hours after the first infusion.
Pharmacokinetics: time to maximum plasma concentration [Tmax] of STP7.
Time to maximum plasma concentration of STP7.
Time frame: Day 5, day 6, day 7, day 8 and day 9: prior to the morning dose and 4 hours post-dose for each day.
Pharmacokinetics: time to maximum plasma concentration [Tmax] of STP7.
Time to maximum plasma concentration of STP7.
Time frame: Day 10, at pre-dose, 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours post-dose.
Pharmacokinetics: area under the concentration-time curve from time 0 to time t of cocaine.
Area under the concentration-time curve from time 0 to time t (AUC0-t) of cocaine.
Time frame: Day 2 and day 10: at 15 minutes before the first infusion, and at 5, 15, 30, 65, 75, 90, 120, 150, and 180 minutes, and at 4, 8, 12, 20 and 32 hours after the first infusion.
Pharmacokinetics: area under the concentration-time curve from time 0 to time t of benzoylecgonine.
Area under the concentration-time curve from time 0 to time t (AUC0-t) of benzoylecgonine.
Time frame: Day 2 and day 10: at 15 minutes before the first infusion, and at 5, 15, 30, 65, 75, 90, 120, 150, and 180 minutes, and at 4, 8, 12, 20 and 32 hours after the first infusion.
Pharmacokinetics: area under the concentration-time curve from time 0 to time of STP7.
Area under the concentration-time curve from time 0 to time t (AUC0-t) of STP7.
Time frame: Day 5, day 6, day 7, day 8 and day 9: prior to the morning dose and 4 hours post-dose for each day.
Pharmacokinetics: area under the concentration-time curve from time 0 to time of STP7.
Area under the concentration-time curve from time 0 to time t (AUC0-t) of STP7.
Time frame: Day 10, at pre-dose, 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours post-dose.
Pharmacokinetics: area under the concentration-time curve from time 0 to 12 hours post-dose of cocaine.
Area under the concentration-time curve from time 0 to 12 hours post-dose (AUC0-12) of cocaine.
Time frame: Day 2 and day 10: at 15 minutes before the first infusion, and at 5, 15, 30, 65, 75, 90, 120, 150, and 180 minutes, and at 4, 8, 12, 20 and 32 hours after the first infusion.
Pharmacokinetics: area under the concentration-time curve from time 0 to 12 hours post-dose of benzoylecgonine.
Area under the concentration-time curve from time 0 to 12 hours post-dose (AUC0-12) of benzoylecgonine.
Time frame: Day 2 and day 10: at 15 minutes before the first infusion, and at 5, 15, 30, 65, 75, 90, 120, 150, and 180 minutes, and at 4, 8, 12, 20 and 32 hours after the first infusion.
Pharmacokinetics: area under the concentration-time curve from time 0 to 12 hours post-dose of STP7.
Area under the concentration-time curve from time 0 to 12 hours post-dose (AUC0-12) of STP7.
Time frame: Day 5, day 6, day 7, day 8 and day 9: prior to the morning dose and 4 hours post-dose for each day.
Pharmacokinetics: area under the concentration-time curve from time 0 to 12 hours post-dose of STP7.
Area under the concentration-time curve from time 0 to 12 hours post-dose (AUC0-12) of STP7.
Time frame: Day 10, at pre-dose, 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours post-dose.
Pharmacokinetics: area under the concentration-time curve from time 0 to time infinity post-dose of cocaine.
Area under the concentration-time curve from time 0 to time infinity post-dose of cocaine.
Time frame: Day 2 and day 10: at 15 minutes before the first infusion, and at 5, 15, 30, 65, 75, 90, 120, 150, and 180 minutes, and at 4, 8, 12, 20 and 32 hours after the first infusion.
Pharmacokinetics: area under the concentration-time curve from time 0 to time infinity post-dose of benzoylecgonine.
Area under the concentration-time curve from time 0 to time infinity post-dose of benzoylecgonine.
Time frame: Day 2 and day 10: at 15 minutes before the first infusion, and at 5, 15, 30, 65, 75, 90, 120, 150, and 180 minutes, and at 4, 8, 12, 20 and 32 hours after the first infusion.
Pharmacokinetics: area under the concentration-time curve from time 0 to time infinity post-dose of STP7.
Area under the concentration-time curve from time 0 to time infinity post-dose of STP7.
Time frame: Day 5, day 6, day 7, day 8 and day 9: prior to the morning dose and 4 hours post-dose for each day.
Pharmacokinetics: area under the concentration-time curve from time 0 to time infinity post-dose of STP7.
Area under the concentration-time curve from time 0 to time infinity post-dose of STP7.
Time frame: Day 10, at pre-dose, 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours post-dose.
Pharmacokinetics: trough plasma concentration (Ctrough) of cocaine.
Trough plasma concentration (Ctrough) of cocaine.
Time frame: Day 2 and day 10: at 15 minutes before the first infusion, and at 5, 15, 30, 65, 75, 90, 120, 150, and 180 minutes, and at 4, 8, 12, 20 and 32 hours after the first infusion.
Pharmacokinetics: trough plasma concentration (Ctrough) of benzoylecgonine.
Trough plasma concentration (Ctrough) of benzoylecgonine.
Time frame: Day 2 and day 10: at 15 minutes before the first infusion, and at 5, 15, 30, 65, 75, 90, 120, 150, and 180 minutes, and at 4, 8, 12, 20 and 32 hours after the first infusion.
Pharmacokinetics: trough plasma concentration (Ctrough) of STP7.
Trough plasma concentration (Ctrough) of STP7.
Time frame: Day 5, day 6, day 7, day 8 and day 9: prior to the morning dose and 4 hours post-dose for each day.
Pharmacokinetics: trough plasma concentration (Ctrough) of STP7.
Trough plasma concentration (Ctrough) of STP7.
Time frame: Day 10, at pre-dose, 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours post-dose.
Pharmacokinetics: terminal rate constant of cocaine.
Terminal rate constant of cocaine.
Time frame: Day 2 and day 10: at 15 minutes before the first infusion, and at 5, 15, 30, 65, 75, 90, 120, 150, and 180 minutes, and at 4, 8, 12, 20 and 32 hours after the first infusion.
Pharmacokinetics: terminal rate constant of benzoylecgonine.
Terminal rate constant of benzoylecgonine.
Time frame: Day 2 and day 10: at 15 minutes before the first infusion, and at 5, 15, 30, 65, 75, 90, 120, 150, and 180 minutes, and at 4, 8, 12, 20 and 32 hours after the first infusion.
Pharmacokinetics: terminal rate constant of STP7.
Terminal rate constant of STP7.
Time frame: Day 5, day 6, day 7, day 8 and day 9: prior to the morning dose and 4 hours post-dose for each day.
Pharmacokinetics: terminal rate constant of STP7.
Terminal rate constant of STP7.
Time frame: Day 10, at pre-dose, 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours post-dose.
Pharmacokinetics: half-life of cocaine.
Half-life (t1/2) of cocaine
Time frame: Day 2 and day 10: at 15 minutes before the first infusion, and at 5, 15, 30, 65, 75, 90, 120, 150, and 180 minutes, and at 4, 8, 12, 20 and 32 hours after the first infusion.
Pharmacokinetics: half-life of benzoylecgonine.
Half-life (t1/2) of benzoylecgonine.
Time frame: Day 2 and day 10: at 15 minutes before the first infusion, and at 5, 15, 30, 65, 75, 90, 120, 150, and 180 minutes, and at 4, 8, 12, 20 and 32 hours after the first infusion.
Pharmacokinetics: half-life of STP7.
Half-life (t1/2) of STP7.
Time frame: Day 5, day 6, day 7, day 8 and day 9: prior to the morning dose and 4 hours post-dose for each day.
Pharmacokinetics: half-life of STP7.
Half-life (t1/2) of STP7.
Time frame: Day 10, at pre-dose, 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours post-dose.
Pharmacokinetics: clearance of cocaine.
Clearance (CL) of cocaine.
Time frame: Day 2 and day 10: at 15 minutes before the first infusion, and at 5, 15, 30, 65, 75, 90, 120, 150, and 180 minutes, and at 4, 8, 12, 20 and 32 hours after the first infusion.
Pharmacokinetics: clearance of benzoylecgonine.
Clearance (CL) of benzoylecgonine.
Time frame: Day 2 and day 10: at 15 minutes before the first infusion, and at 5, 15, 30, 65, 75, 90, 120, 150, and 180 minutes, and at 4, 8, 12, 20 and 32 hours after the first infusion.
Pharmacokinetics: clearance of STP7.
Clearance (CL) of STP7.
Time frame: Day 5, day 6, day 7, day 8 and day 9: prior to the morning dose and 4 hours post-dose for each day.
Pharmacokinetics: clearance of STP7.
Clearance (CL) of STP7.
Time frame: Day 10, at pre-dose, 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours post-dose.
Pharmacokinetics: Clearance from plasma after oral administration of cocaine.
Clearance from plasma after oral administration (CL/F) of cocaine.
Time frame: Day 2 and day 10: at 15 minutes before the first infusion, and at 5, 15, 30, 65, 75, 90, 120, 150, and 180 minutes, and at 4, 8, 12, 20 and 32 hours after the first infusion.
Pharmacokinetics: Clearance of benzoylecgonine from plasma after oral administration (CL/F) of cocaine.
Clearance of benzoylecgonine from plasma after oral administration (CL/F) of cocaine.
Time frame: Day 2 and day 10: at 15 minutes before the first infusion, and at 5, 15, 30, 65, 75, 90, 120, 150, and 180 minutes, and at 4, 8, 12, 20 and 32 hours after the first infusion.
Pharmacokinetics: Clearance from plasma after oral administration (CL/F) of STP7.
Clearance from plasma after oral administration (CL/F) of STP7.
Time frame: Day 5, day 6, day 7, day 8 and day 9: prior to the morning dose and 4 hours post-dose for each day.
Pharmacokinetics: Clearance from plasma after oral administration (CL/F) of STP7.
Clearance from plasma after oral administration (CL/F) of STP7.
Time frame: Day 10, at pre-dose, 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours post-dose.
Visual evaluation of the STP7 on the subjective effects of cocaine at screening
To evaluate whether STP7 treatment alters the subjective effects of cocaine measured by Visual Analog Scales (VAS).
Time frame: Day -2: 30 minutes prior to cocaine infusion and at 5, 10, 15, 30, 45, 55, 65, 70, 75, 90, 105, 115, 125, 130, 135, 150, 165 and 180 minutes after the first infusion.
Visual evaluation of the STP7 on the subjective effects of cocaine at baseline and during treatment
To evaluate whether STP7 treatment alters the subjective effects of cocaine measured by Visual Analog Scales (VAS).
Time frame: Day 1, day 2, day 9 and day 10: at -30, 5, 10, 15, 30, 45, 55, 65, 70, 75, 90, 105 and 120 minutes after the first infusion.
Craving evaluation of the STP7 on the subjective effects of cocaine.
To evaluate whether STP7 treatment alters the subjective effects of cocaine on craving measured by the score of the Brief Substance Craving Scale (BSCS).
Time frame: Day -2, day 1, day 2, day 9 and day 10: at pre-infusion and 125 minutes after the start of the cocaine infusion.
Ran from Apr 2024 to primary completion in Oct 2024, 5 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Mavoglurant · Cocaine
Stalicla SA